[1] Katz R. FDA: Evidentiary standards for drug development and approval. NeuroRx. 2004; 1: 307–316.
[2] Goodman SN. P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate. Am J Epidemiol. 1993; 137: 485–496.
[3] Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999; 130: 995–1004.
[4] Food and Drug Administration. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. Maryland: United States Food and Drug Administration; 1998.
[5] van Ravenzwaaij D, Ioannidis JP. A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results. PloS one. 2017; 12: e0173184.
[6] Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med. 1999; 130: 1005–1013.
[7] Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine. 2008; 358: 252–60.
[8] Ioannidis JPA. Why most published research findings are false. PLOS Med. 2005; 2: e124.
[9] Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, Bollen KA, Brembs B, Brown L, Camerer C, Cesarini D, et al. Redefine statistical significance. Nature Human Behaviour. 2018; 2: 6.
[10] Jeffreys H. Theory of probability. 1st ed. Oxford, UK: Oxford University Press; 1961.
[11] Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc. 1995; 90: 773–795.
[12] Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP. New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev. 2012; 10: MR000024.
[13] Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. The Lancet. 2000; 356: 635–8.
[14] Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive?. J. Natl. Cancer Inst. 2010; 103: 16–20.[15] Pereira TV, Horwitz RI, Ioannidis JPA. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012; 308: 1676–84.
[16] Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet. 2018; 391: 1357–66.
[17] Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: Comparative study of articles indexed in PubMed. BMJ. 2010; 340: c723.
[18] In ‘t Hout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Medical Research Methodology. 2014; 14: 25.
[19] Rouder JN, Speckman PL, Sun D, Morey RD, Iverson G. Bayesian t tests for accepting and rejecting the null hypothesis. Psychon Bull Rev. 2009;16: 225–37.
[20] Morey RD, Rouder JN, Jamil T, Urbanek, S, Forner, K, Ly, A. BayesFactor: Computation of Bayes factors for common designs. R package version 0.9.12–4.2. 2018.
[21] Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care. 2003; 41; 582–92.
[22] Copay AG, Subach BR, Glassman SD, Polly Jr DW, Schuler TC. Understanding the minimum clinically important difference: A review of concepts and methods. The Spine Journal. 2007; 7: 541–6.
[23] Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. Pharmacoeconomics. 2000; 18: 419–23.
[24] Hobbs BP, Carlin BP. Practical Bayesian design and analysis for drug and device clinical trials. J Biopharm Stat. 2008; 18: 54–80.
[25] Zaslavsky BG. Bayesian Hypothesis Testing in Two-Arm Trials with Dichotomous Outcomes. Biometrics. 2013; 69: 157–163.
[26] Woodcock J, Temple R, Midthun K, Schultz D, Sundlof S. FDA senior management perspectives. Clinical Trials. 2005; 2: 373–8.
[27] Chavalarias D, Wallach JD, Li AHT, Ioannidis JPA. Evolution of reporting p values in the biomedical literature, 1990–2015. J Am Med Assoc. 2016; 315: 1141–1148.
[28] JASP [computer program]. Version 0.7.5.6. The JASP Team; 2016. https://jasp-stats.org/.
[29] van Ravenzwaaij D, Monden R, Tendeiro J, Ioannidis JP. Bayes factors for superiority, non-inferiority, and equivalence designs.